Membrane-embedded CdaA is required for efficient synthesis of second messenger cyclic di-AMP.
Saved in:
| Title: | Membrane-embedded CdaA is required for efficient synthesis of second messenger cyclic di-AMP. |
|---|---|
| Authors: | Foster AJ; Department of Biochemistry, Groningen Biomolecular Science and Biotechnology Institute, University of Groningen, Nijenborgh 3, Groningen, The Netherlands., Li H; Department of Biochemistry, Groningen Biomolecular Science and Biotechnology Institute, University of Groningen, Nijenborgh 3, Groningen, The Netherlands., Drougkas P; Department of Biochemistry, Groningen Biomolecular Science and Biotechnology Institute, University of Groningen, Nijenborgh 3, Groningen, The Netherlands.; Biochemistry Center, Heidelberg University, Im Neuenheimer Feld 328, Heidelberg, Germany., Schuurman-Wolters GK; Department of Biochemistry, Groningen Biomolecular Science and Biotechnology Institute, University of Groningen, Nijenborgh 3, Groningen, The Netherlands., Ten Kate J; Department of Biochemistry, Groningen Biomolecular Science and Biotechnology Institute, University of Groningen, Nijenborgh 3, Groningen, The Netherlands., Paulino C; Biochemistry Center, Heidelberg University, Im Neuenheimer Feld 328, Heidelberg, Germany. cristina.paulino@bzh.uni-heidelberg.de., Poolman B; Department of Biochemistry, Groningen Biomolecular Science and Biotechnology Institute, University of Groningen, Nijenborgh 3, Groningen, The Netherlands. b.poolman@rug.nl. |
| Source: | Communications biology [Commun Biol] 2024 Dec 30; Vol. 7 (1), pp. 1710. Date of Electronic Publication: 2024 Dec 30. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Group UK Country of Publication: England NLM ID: 101719179 Publication Model: Electronic Cited Medium: Internet ISSN: 2399-3642 (Electronic) Linking ISSN: 23993642 NLM ISO Abbreviation: Commun Biol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
